Clinical and toxicological aspects of the antineoplastic drug cladribine: A review

@article{Guchelaar1994ClinicalAT,
  title={Clinical and toxicological aspects of the antineoplastic drug cladribine: A review},
  author={Henk-Jan Guchelaar and Dick J. Richel and Martyn Ronald Schaafsma},
  journal={Annals of Hematology},
  year={1994},
  volume={69},
  pages={223-230}
}
Cladribine (2-chlorodeoxyadenosine, 2-CdA) is a new antineoplastic drug which exerts its antilymphoproliferative activity by its resistance to the enzyme adenosine deaminase. Cladribine is mostly administered as a 7-day continuous infusion and in a dose of 0.1 mg/kg/day. However, preliminary data show that the subcutaneous and oral routes of administration might be feasible. The drug is well tolerated, and myelosuppression was found to be the dose-limiting toxicity. Nonhematological toxicity… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Similar Papers

Loading similar papers…